Macular Degeneration Treatment Market to Grow with a CAGR of 8.30% through 2029

The increasing burden of retinal disorders is expected to drive the Global Macular Degeneration Treatment Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Macular Degeneration Treatment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Macular Degeneration Treatment Market stood at USD 13.10 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.30% through 2029. The increasing incidence of retinal diseases has spurred the demand for macular degeneration treatment. Eye ailments have emerged as significant concerns in both developed and developing nations. Globally, there is a noticeable uptick in the prevalence of severe eye conditions, with vision impairment posing a substantial public health challenge. The World Health Organization (WHO) has identified numerous retinal diseases that hinder vision on a global scale. Among these, refractive errors and age-related macular disorders are particularly prevalent in less developed regions. Given the escalating prevalence of retinal disorders, it is expected that the market for macular degeneration treatment will witness significant expansion over the forecast period.

Augmented research and development (R&D) efforts, alongside a surge in clinical trials, stand as significant drivers for market expansion. Notably, in January 2021, Novartis AG initiated a phase III clinical trial to assess the efficacy and safety of brolucizumab in patients with neovascular age-related macular degeneration. These advancements are propelling the growth of the macular degeneration market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Macular Degeneration Treatment Market”

Global Macular Degeneration Treatment Market is segmented into Type, Stage of Disease, Treatment Type, Sales Channel, regional distribution, and company.

Based on the Type, The segment Wet Age-related Macular Degeneration is expected to experience significant market growth throughout the forecast period. The expansion of the Global Macular Degeneration Treatment Market is largely driven by the prevalence of Wet Age-related Macular Degeneration (wet AMD), which serves as a key driver for advanced treatment demand. Wet AMD, characterized by abnormal blood vessel growth in the retina, poses a serious threat to vision and requires timely and precise intervention. The urgency surrounding wet AMD treatment generates substantial market demand for innovative pharmaceuticals and therapies. Pharmaceutical firms are heavily investing in research and development to introduce new drugs and therapies tailored to tackle the complexities of wet AMD. The breakthrough introduction of anti-VEGF (Vascular Endothelial Growth Factor) drugs, which inhibit abnormal blood vessel growth, has revolutionized wet AMD treatment. With the global aging population expanding, the incidence of wet AMD is increasing, further propelling market growth.

In the Treatment Type, drug segment emerged as the predominant force in the market. The growth trajectory of the Global Macular Degeneration Treatment Market is significantly influenced by the advancement and diversification of drug treatment options. Pharmaceutical innovations play a crucial role in shaping market dynamics, with continual improvements in drug therapies driving sustained expansion. Particularly noteworthy is the transformative impact of anti-VEGF (Vascular Endothelial Growth Factor) drugs on macular degeneration treatment, particularly in addressing the wet form of the disease. These drugs, administered via injections, effectively suppress abnormal blood vessel growth in the retina, heralding a paradigm shift in treatment approaches.

Major companies operating in Global Macular Degeneration Treatment Market are:

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc,
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Advanced age-related macular degeneration is considered a leading cause of irreversible blindness and visual impairment across the world. Thus, the increasing burden of age-related macular degeneration is fueling market growth. Furthermore, beneficial government initiatives, an increase in the number of research partnerships, and the presence of the key market players, coupled with recent product launches, are anticipated to boost the growth of the market in the North American region. However, mid-size to small companies are increasing their market presence with product innovations by introducing new products. Furthermore, the American Macular Degeneration Foundation (AMDF) in the United States disseminated this information to warn age-related macular degeneration (AMD) patients and eye care practitioners about the potential risk.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Macular Degeneration Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD), By Treatment Type (Drug, Devices, Surgery), By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other), By Region, By Competition 2019-2029F”, has evaluated the future growth potential of Global Macular Degeneration Treatment Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Macular Degeneration Treatment Market.

Contact

TechSci Research LLC

420 Lexington Avenue,

Suite 300, New York,

United States- 10170

M: +13322586602

Email: [email protected]

Website: https://www.techsciresearch.com